neuromuscular disease
Conditions
Interventions
None listed
Sponsors
Chugai Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have been diagnosed with the target neuromuscular disease during the enrollment period and can be continuously observed from March 2019 to February 2021
Exclusion criteria
Exclusion criteria: No setting
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Status of concurrent diagnosis, frequency of medical treatment, medical expenses, period from the date of initial diagnosis to the start of medical treatment | — |
Countries
Japan
Contacts
Public ContactSadaoki Sakai
Chugai Pharmaceutical Co., Ltd. Medical Affairs Devision
Outcome results
None listed